Lin Elizabeth Yeu's Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Sep 9, 2026
- Accession no.
- 0001842190-26-000011
- Filed
- Sep 9, 2026, 4:13 PM ET
- Trade date
- Sep 4, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $1.22M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lin Elizabeth YeuCIK 0001842190 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Common Stock | SSaleDisposed | −5,387 | $85.00 | −$457,895 | 7,933 | Direct | |
| Sep 4, 2026 | Common Stock | SSaleDisposed | −5,386 | $90.00 | −$484,740 | 2,547 | Direct | |
| Sep 4, 2026 | Common Stock | SSaleDisposed | −1,590 | $85.00 | −$135,150 | 3,180 | Indirect | |
| Sep 4, 2026 | Common Stock | SSaleDisposed | −1,590 | $90.00 | −$143,100 | 1,590 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.